Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer
Open Access
- 31 August 2009
- journal article
- review article
- Published by Elsevier BV in The Breast
- Vol. 18, S1-S11
- https://doi.org/10.1016/s0960-9776(09)70002-5
Abstract
No abstract availableFunding Information
- AstraZeneca
This publication has 78 references indexed in Scilit:
- Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnnals of Oncology, 2009
- Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patientsCancer, 2008
- Practical guidance for the management of aromatase inhibitor-associated bone lossAnnals of Oncology, 2008
- Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Surviving recurrence: Psychological and quality‐of‐life recoveryCancer, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Adherence to MedicationNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Is breast cancer survival improving?Cancer, 2003